Development of pegylated MTI-101 for the treatment of relapsed myeloma
Ended Project Grant Awarded Last action
- Award ID
- R44CA221554
- Recipient
-
Modulation Therapeutics, Inc. UEI FPRRYGJGEHB1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,434,274
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Everettville, WV 26505, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $212,660 | |
| Amendment | $0 | |
| Amendment | $763,695 | |
| Amendment | $0 | |
| Amendment | $4,318 | |
| Amendment | $1,161,570 | |
| Amendment | $49,975 | |
| Original award | $242,056 |
Show all 13
Quick answers
Who received award R44CA221554?
R44CA221554 was awarded to Modulation Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2017.
How much is award R44CA221554 worth?
$2,434,274 has been obligated on R44CA221554.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award